Ipamorelin: Raun, Gobburu, Beck, and the rest

Beck beside Raun and Gobburu

The Beck bowel-resection trial is the published patient-benefit test. It asked about the first tolerated meal and missed the primary endpoint. Beside it, the Gobburu healthy-volunteer study describes drug kinetics and a hormone pulse in healthy men.

The Raun founding characterization explains the selective growth-hormone response in cells, rats and pigs. I would put these papers next to one another on the desk: the reason for optimism, the human blood result and the patient result are easier to distinguish when they remain together.

Animal outcomes and the related-compound safety paper

The Johansen rat-bone paper concerns longitudinal growth, with no measured change in total systemic IGF-1. The Lu ferret paper concerns chemotherapy-associated weight loss and vomiting. Both are animal studies.

The Stokes cardiovascular-toxicity paper tested a different ghrelin-receptor agonist in rats. It deserves a place in the safety discussion, with that distinction intact. It records rat injury with a different molecule.

Context, chemical identity and the newer reviews

The Camilleri gastrointestinal review and Zatorski ghrelin-agonist review provide class context, rather than new ipamorelin patient results. The Krug product analysis and Gajda seized-material analysis concern chemical identity and modified analogues. The Coutinho sports review addresses use and anti-doping concerns.

The remaining reviews cover aging, musculoskeletal injuries and performance, metabolic, endocrine and aesthetic conditions and injectable peptides in sports medicine. Their assessments of gaps are useful; their publication dates do not fill those gaps with new patients.

The complete bibliographic entries follow.